Asthma biologic trial eligibility and real-world outcomes in the United States.

ABSTRACT:

Objective

To compare the outcomes of real-world patients who would have been eligible for asthma biologics to those who would not have been eligible.

Methods

We used data from the OptumLabs Data Warehouse (OLDW) to categorize patients into eligible and ineligible groups based on clinical trials (n = 19 trials) used for Food and Drug Administration (FDA) approval. We then compared the change in the number of asthma exacerbations before and after biological initiation between the two groups.

Results

The percentage of people who would have been eligible for asthma biologic clinical trials ranged from 0-10.2%. The eligible group had a greater reduction in number of asthma exacerbations compared to the ineligible group based on eligibility criteria from 1 omalizumab

SUBMITTER: Lam RW 

PROVIDER: S-EPMC9575703 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature